Cost and outcomes of paediatric antiretroviral treatment in South Africa.
Identifieur interne : 001955 ( Ncbi/Merge ); précédent : 001954; suivant : 001956Cost and outcomes of paediatric antiretroviral treatment in South Africa.
Auteurs : Gesine Meyer-Rath [États-Unis] ; Alana Brennan ; Lawrence Long ; Buyiswa Ndibongo ; Karl Technau ; Harry Moultrie ; Lee Fairlie ; Ashraf Coovadia ; Sydney RosenSource :
- AIDS (London, England) [ 1473-5571 ] ; 2013.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice (économie), Antirétroviraux (usage thérapeutique), Antirétroviraux (économie), Charge virale, Coûts des soins de santé, Enfant, Enfant d'âge préscolaire, Humains, Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Infections à VIH (économie), Nourrisson, Numération des lymphocytes CD4, République d'Afrique du Sud, Résultat thérapeutique, Études de cohortes.
- MESH :
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Antirétroviraux.
- virologie : Infections à VIH.
- économie : Analyse coût-bénéfice, Antirétroviraux, Infections à VIH.
- Charge virale, Coûts des soins de santé, Enfant, Enfant d'âge préscolaire, Humains, Nourrisson, Numération des lymphocytes CD4, République d'Afrique du Sud, Résultat thérapeutique, Études de cohortes.
- Wicri :
- geographic : Afrique du Sud.
English descriptors
- KwdEn :
- Anti-Retroviral Agents (economics), Anti-Retroviral Agents (therapeutic use), CD4 Lymphocyte Count, Child, Child, Preschool, Cohort Studies, Cost-Benefit Analysis (economics), HIV Infections (drug therapy), HIV Infections (economics), HIV Infections (virology), Health Care Costs, Humans, Infant, South Africa, Treatment Outcome, Viral Load.
- MESH :
- chemical , economics : Anti-Retroviral Agents.
- chemical , therapeutic use : Anti-Retroviral Agents.
- geographic : South Africa.
- drug therapy : HIV Infections.
- economics : Cost-Benefit Analysis, HIV Infections.
- virology : HIV Infections.
- CD4 Lymphocyte Count, Child, Child, Preschool, Cohort Studies, Health Care Costs, Humans, Infant, Treatment Outcome, Viral Load.
Abstract
Little is known about the cost of paediatric antiretroviral treatment (ART) in low-income and middle-income countries. We analysed the average cost of providing paediatric ART in South Africa during the first 2 years after ART initiation, stratified by patient outcomes.
DOI: 10.1097/QAD.0b013e32835a5b92
PubMed: 23014517
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001426
- to stream PubMed, to step Curation: 001426
- to stream PubMed, to step Checkpoint: 001426
Links to Exploration step
pubmed:23014517Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost and outcomes of paediatric antiretroviral treatment in South Africa.</title><author><name sortKey="Meyer Rath, Gesine" sort="Meyer Rath, Gesine" uniqKey="Meyer Rath G" first="Gesine" last="Meyer-Rath">Gesine Meyer-Rath</name><affiliation wicri:level="1"><nlm:affiliation>Center for Global Health and Development, Boston University, Boston, Massachusetts 02118, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Global Health and Development, Boston University, Boston, Massachusetts 02118</wicri:regionArea><wicri:noRegion>Massachusetts 02118</wicri:noRegion></affiliation></author><author><name sortKey="Brennan, Alana" sort="Brennan, Alana" uniqKey="Brennan A" first="Alana" last="Brennan">Alana Brennan</name></author><author><name sortKey="Long, Lawrence" sort="Long, Lawrence" uniqKey="Long L" first="Lawrence" last="Long">Lawrence Long</name></author><author><name sortKey="Ndibongo, Buyiswa" sort="Ndibongo, Buyiswa" uniqKey="Ndibongo B" first="Buyiswa" last="Ndibongo">Buyiswa Ndibongo</name></author><author><name sortKey="Technau, Karl" sort="Technau, Karl" uniqKey="Technau K" first="Karl" last="Technau">Karl Technau</name></author><author><name sortKey="Moultrie, Harry" sort="Moultrie, Harry" uniqKey="Moultrie H" first="Harry" last="Moultrie">Harry Moultrie</name></author><author><name sortKey="Fairlie, Lee" sort="Fairlie, Lee" uniqKey="Fairlie L" first="Lee" last="Fairlie">Lee Fairlie</name></author><author><name sortKey="Coovadia, Ashraf" sort="Coovadia, Ashraf" uniqKey="Coovadia A" first="Ashraf" last="Coovadia">Ashraf Coovadia</name></author><author><name sortKey="Rosen, Sydney" sort="Rosen, Sydney" uniqKey="Rosen S" first="Sydney" last="Rosen">Sydney Rosen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23014517</idno><idno type="pmid">23014517</idno><idno type="doi">10.1097/QAD.0b013e32835a5b92</idno><idno type="wicri:Area/PubMed/Corpus">001426</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001426</idno><idno type="wicri:Area/PubMed/Curation">001426</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001426</idno><idno type="wicri:Area/PubMed/Checkpoint">001426</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001426</idno><idno type="wicri:Area/Ncbi/Merge">001955</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost and outcomes of paediatric antiretroviral treatment in South Africa.</title><author><name sortKey="Meyer Rath, Gesine" sort="Meyer Rath, Gesine" uniqKey="Meyer Rath G" first="Gesine" last="Meyer-Rath">Gesine Meyer-Rath</name><affiliation wicri:level="1"><nlm:affiliation>Center for Global Health and Development, Boston University, Boston, Massachusetts 02118, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Global Health and Development, Boston University, Boston, Massachusetts 02118</wicri:regionArea><wicri:noRegion>Massachusetts 02118</wicri:noRegion></affiliation></author><author><name sortKey="Brennan, Alana" sort="Brennan, Alana" uniqKey="Brennan A" first="Alana" last="Brennan">Alana Brennan</name></author><author><name sortKey="Long, Lawrence" sort="Long, Lawrence" uniqKey="Long L" first="Lawrence" last="Long">Lawrence Long</name></author><author><name sortKey="Ndibongo, Buyiswa" sort="Ndibongo, Buyiswa" uniqKey="Ndibongo B" first="Buyiswa" last="Ndibongo">Buyiswa Ndibongo</name></author><author><name sortKey="Technau, Karl" sort="Technau, Karl" uniqKey="Technau K" first="Karl" last="Technau">Karl Technau</name></author><author><name sortKey="Moultrie, Harry" sort="Moultrie, Harry" uniqKey="Moultrie H" first="Harry" last="Moultrie">Harry Moultrie</name></author><author><name sortKey="Fairlie, Lee" sort="Fairlie, Lee" uniqKey="Fairlie L" first="Lee" last="Fairlie">Lee Fairlie</name></author><author><name sortKey="Coovadia, Ashraf" sort="Coovadia, Ashraf" uniqKey="Coovadia A" first="Ashraf" last="Coovadia">Ashraf Coovadia</name></author><author><name sortKey="Rosen, Sydney" sort="Rosen, Sydney" uniqKey="Rosen S" first="Sydney" last="Rosen">Sydney Rosen</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Retroviral Agents (economics)</term><term>Anti-Retroviral Agents (therapeutic use)</term><term>CD4 Lymphocyte Count</term><term>Child</term><term>Child, Preschool</term><term>Cohort Studies</term><term>Cost-Benefit Analysis (economics)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (economics)</term><term>HIV Infections (virology)</term><term>Health Care Costs</term><term>Humans</term><term>Infant</term><term>South Africa</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice (économie)</term><term>Antirétroviraux (usage thérapeutique)</term><term>Antirétroviraux (économie)</term><term>Charge virale</term><term>Coûts des soins de santé</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Humains</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Infections à VIH (économie)</term><term>Nourrisson</term><term>Numération des lymphocytes CD4</term><term>République d'Afrique du Sud</term><term>Résultat thérapeutique</term><term>Études de cohortes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Anti-Retroviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Retroviral Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>South Africa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Cost-Benefit Analysis</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirétroviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Antirétroviraux</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>CD4 Lymphocyte Count</term><term>Child</term><term>Child, Preschool</term><term>Cohort Studies</term><term>Health Care Costs</term><term>Humans</term><term>Infant</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Charge virale</term><term>Coûts des soins de santé</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Humains</term><term>Nourrisson</term><term>Numération des lymphocytes CD4</term><term>République d'Afrique du Sud</term><term>Résultat thérapeutique</term><term>Études de cohortes</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Afrique du Sud</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Little is known about the cost of paediatric antiretroviral treatment (ART) in low-income and middle-income countries. We analysed the average cost of providing paediatric ART in South Africa during the first 2 years after ART initiation, stratified by patient outcomes.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23014517</PMID><DateCreated><Year>2012</Year><Month>12</Month><Day>17</Day></DateCreated><DateCompleted><Year>2013</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2012</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>Cost and outcomes of paediatric antiretroviral treatment in South Africa.</ArticleTitle><Pagination><MedlinePgn>243-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e32835a5b92</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Little is known about the cost of paediatric antiretroviral treatment (ART) in low-income and middle-income countries. We analysed the average cost of providing paediatric ART in South Africa during the first 2 years after ART initiation, stratified by patient outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We collected data on outpatient resource use and treatment outcomes of 288 children in two Johannesburg public clinics, Empilweni Services and Research Unit (ESRU) and Harriet Shezi Children's Clinic (HSCC) from 2005 to 2009. Patient-level resource use was estimated from patient records. Unit cost data came from site accounts and public-sector sources. Patient outcomes at month 12 and 24 after initiation were defined based on patients' weight CD4 cell counts/percentages, viral loads, and the presence of new WHO stage 3/4 conditions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Median age/CD4 percentage at initiation was 4.03 years/12.40% in ESRU and 5.84 years/14.05% in HSCC, respectively. Sixty-two and 91% of patients remained in care and responding to treatment at month 12 in ESRU and HSCC, respectively, and 68 and 80% at month 24. The average cost per patient in care and responding was US$ 830 in year 1 and US$ 717 in year 2 in ESRU and US$ 678 and US$ 782 in HSCC. Antiretroviral drugs comprised 33-52% of total cost, clinic visits 23-31%, lab tests 12-16%, and fixed costs 8-18%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Costs varied between the two clinics but were comparable with those of adult ART. Few very young children accessed ART in either clinic and those who did were already very ill, emphasizing the importance of early infant treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer-Rath</LastName><ForeName>Gesine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Global Health and Development, Boston University, Boston, Massachusetts 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Alana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ndibongo</LastName><ForeName>Buyiswa</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Technau</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Moultrie</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fairlie</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Coovadia</LastName><ForeName>Ashraf</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Sydney</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D044966" MajorTopicYN="N">Anti-Retroviral Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23014517</ArticleId><ArticleId IdType="doi">10.1097/QAD.0b013e32835a5b92</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Brennan, Alana" sort="Brennan, Alana" uniqKey="Brennan A" first="Alana" last="Brennan">Alana Brennan</name><name sortKey="Coovadia, Ashraf" sort="Coovadia, Ashraf" uniqKey="Coovadia A" first="Ashraf" last="Coovadia">Ashraf Coovadia</name><name sortKey="Fairlie, Lee" sort="Fairlie, Lee" uniqKey="Fairlie L" first="Lee" last="Fairlie">Lee Fairlie</name><name sortKey="Long, Lawrence" sort="Long, Lawrence" uniqKey="Long L" first="Lawrence" last="Long">Lawrence Long</name><name sortKey="Moultrie, Harry" sort="Moultrie, Harry" uniqKey="Moultrie H" first="Harry" last="Moultrie">Harry Moultrie</name><name sortKey="Ndibongo, Buyiswa" sort="Ndibongo, Buyiswa" uniqKey="Ndibongo B" first="Buyiswa" last="Ndibongo">Buyiswa Ndibongo</name><name sortKey="Rosen, Sydney" sort="Rosen, Sydney" uniqKey="Rosen S" first="Sydney" last="Rosen">Sydney Rosen</name><name sortKey="Technau, Karl" sort="Technau, Karl" uniqKey="Technau K" first="Karl" last="Technau">Karl Technau</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Meyer Rath, Gesine" sort="Meyer Rath, Gesine" uniqKey="Meyer Rath G" first="Gesine" last="Meyer-Rath">Gesine Meyer-Rath</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001955 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001955 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:23014517
|texte= Cost and outcomes of paediatric antiretroviral treatment in South Africa.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:23014517" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |